ArticleFrontiers in medicine2026
Efficacy of a reduced-drug burden quadruple therapy with vonoprazan, cefuroxime, minocycline, and bismuth for
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Few studies have evaluated the efficacy and safety of vonoprazan, cefuroxime, minocycline, and bismuth (VCMB) quadruple therapy (with vonoprazan 20 mg once daily and cefuroxime 250 mg twice daily) for Methods: This retrospective analysis enrolled patients treated with a 14-day VCMB quadruple therapy. The included patients were 18-80 years old and positive for Results: A total of 106 patients were enrolled. The intention to treat (ITT) and per-protocol (PP) eradication rates were 90.6% (95% CI: 82.9-95.1) and 96.0% (95% CI: 89.5-98.7). The overall incidence of adverse events was 21.9%. Mild dizziness and nausea were the most common adverse events, and these symptoms resolved spontaneously without additional treatment. Conclusions: The 14-day VCMB quadruple therapy, in which both vonoprazan and cefuroxime were administered at half their usual total daily doses, achieved a favorable
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.